Bharat Biotech partnered with Alopexx, Inc. to jointly develop and commercialize Alopexx’s broad-spectrum antimicrobial vaccine, AV0328, in India and other low and lower-middle-income nations.
Bharat Biotech, known for its research, development, and manufacturing expertise in biotechnology, will collaborate with Alopexx, a clinical-stage company specializing in immune mediated therapies aimed at preventing and treating infections caused by bacteria, fungi, and parasites.
The brands will jointly develop and market AV0328, a synthetic vaccine aimed at poly N-acetyl glucosamine (PNAG), in India and other licensed regions. Dr. Krishna Ella, Executive Chairman, Bharat Biotech said, “Our objective is to combat antimicrobial resistance through vaccination, and this partnership supports our mission to deliver safe, affordable, and high-quality vaccines to fight infectious diseases globally”.
As reported by financialexpress.com, AV0328 targets PNAG, a component found on the surface of various bacterial, fungal, and parasitic pathogens.
Dr. Daniel Vlock, CEO, Alopexx added, “The partnership is a significant step toward providing accessible, broad-spectrum antimicrobial solutions, particularly in low and middle income countries”.
